Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.

Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM.

Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123. Epub 2012 Nov 1.

2.

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.

Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.

3.

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1702-12.

PMID:
22986437
4.

Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.

Rao SS, Quigley EM, Shiff SJ, Lavins BJ, Kurtz CB, MacDougall JE, Currie MG, Johnston JM.

Clin Gastroenterol Hepatol. 2014 Apr;12(4):616-23. doi: 10.1016/j.cgh.2013.09.022. Epub 2013 Sep 25.

5.

Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.

Videlock EJ, Cheng V, Cremonini F.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2.

PMID:
23644388
6.

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.

Lacy BE, Lembo AJ, Macdougall JE, Shiff SJ, Kurtz CB, Currie MG, Johnston JM.

Neurogastroenterol Motil. 2014 Mar;26(3):326-33. doi: 10.1111/nmo.12264. Epub 2013 Dec 30.

7.

Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.

McCormack PL.

Drugs. 2014 Jan;74(1):53-60. doi: 10.1007/s40265-013-0157-5. Review.

PMID:
24293117
8.

A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.

Johnston JM, Shiff SJ, Quigley EM.

Curr Med Res Opin. 2013 Feb;29(2):149-60. doi: 10.1185/03007995.2012.754743. Epub 2012 Dec 20. Review.

PMID:
23198977
9.

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.

Lacy BE, Schey R, Shiff SJ, Lavins BJ, Fox SM, Jia XD, Blakesley RE, Hao X, Cronin JA, Currie MG, Kurtz CB, Johnston JM, Lembo AJ.

PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015.

10.

Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.

Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, Magni E, Porro GB.

Eur Rev Med Pharmacol Sci. 2010 Mar;14(3):155-62.

PMID:
20391952
11.

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.

Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.

Gut. 2005 Dec;54(12):1707-13. Epub 2005 Jul 14.

12.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

13.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, MacDougall JE, Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM.

Gastroenterology. 2013 Dec;145(6):1334-46.e1-11. doi: 10.1053/j.gastro.2013.08.017. Epub 2013 Aug 16.

14.

Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.

Huang H, Taylor DC, Carson RT, Sarocco P, Friedman M, Munsell M, Blum SI, Menzin J.

J Med Econ. 2015 Apr;18(4):283-94. doi: 10.3111/13696998.2014.979291.

PMID:
25333331
15.

Review article: Linaclotide for the management of irritable bowel syndrome with constipation.

Layer P, Stanghellini V.

Aliment Pharmacol Ther. 2014 Feb;39(4):371-84. doi: 10.1111/apt.12604. Epub 2014 Jan 16. Review.

16.

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

Tack JF, Miner PB Jr, Fischer L, Harris MS.

Aliment Pharmacol Ther. 2011 Oct;34(8):868-77. doi: 10.1111/j.1365-2036.2011.04818.x. Epub 2011 Aug 24.

17.

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003960. Review.

PMID:
17943807
18.

Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.

Love BL, Johnson A, Smith LS.

Am J Health Syst Pharm. 2014 Jul 1;71(13):1081-91. doi: 10.2146/ajhp130575. Review.

PMID:
24939497
19.

Efficacy of linaclotide for patients with chronic constipation.

Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM.

Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.

PMID:
20045700
20.

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.

Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ.

Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089. Epub 2013 Feb 6.

PMID:
23384406

Supplemental Content

Support Center